A Phase III, Multi-center, Open Label, Uncontrolled Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) in Inducing Increased Testicular Volume and Spermatogenesis in Adult Men With Hypogonadotropic Hypogonadism Who Remain Azoospermic When Treated With hCG Alone (Phase III; Protocol No. MK-8962-031-00 [Also Known as SCH 900962, P07937])
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 18
- 主要终点
- Change From Baseline in Log-Transformed Testicular Volume at Week 52
研究概览
简要总结
This study will assess if corifollitropin alfa (MK-8962), when administered in combination with human chorionic gonadotropin (hCG), will increase testicular volume in men with HH who remain azoospermic after treatment with hCG alone.
Hypothesis: The lower limit of the 95% confidence interval for the geometric mean increase in testicular volume from Day 1 to Week 52 is greater than one.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with hypogonadotropic hypogonadism, either congenital or acquired
- •Have low circulating levels of testosterone
- •Have low circulating levels of gonadotropins (follicle stimulating hormone [FSH]; luteinizing hormone)
- •Presence of both scrotal testes
- •Have azoospermia (no measurable level of sperm)
- •Adequate replacement of other pituitary hormones
- •Good general physical and mental health
排除标准
- •Primary hypogonadism, such as Klinefelter's syndrome
- •History of unilateral or bilateral cryptorchidism (maldescended testes)
- •History or presence of testicular pathology of clinical importance (e.g., epididymitis, orchitis, testicular torsion, varicocele stage III, testicular atrophy, occlusive azoospermia, etc), and/or vasectomy
- •Treated with FSH, hCG or gonadotropin-releasing hormone (GnRH) within previous 3 months or for more than 1 month within previous 6 months
- •Proven spermatogenesis with hCG treatment alone
- •Previous unsuccessful attempt with hCG in combination with human menopausal gonadotropin (hMG)/FSH to achieve spermatogenesis
- •Required a dose of hCG of more than 6000 international units (IU) per week in a previous attempt to normalize T levels
- •Untreated pituitary or hypothalamic tumor, or inadequately treated pituitary or hypothalamic tumor that is likely to progress during the study
- •History or presence (known or suspected) of testicular, prostatic or breast cancer
- •Prostate pathology of clinical importance
- •Past or present oncologic treatment (chemo/radiotherapy)
- •Diabetes mellitus
- •Clinically significant, untreated hyperprolactinaemia
- •Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
- •Tested positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
- •User of recreational or illicit drugs or has had a recent history (within the past year) of drug abuse or dependence, or increased alcohol consumption
- •Allergy/sensitivity to gonadotropins or its/their excipients
- •Has received within previous 1 month or plans to use: Hormonal preparations other than the study medication, drugs that are known to impair testicular function, agents known to affect sex hormone secretion and/or drugs that are known or suspected to be teratogenic
- •Used any investigational drugs within three months or actively participating in another study
研究组 & 干预措施
Corifollitropin alfa 150 μg + hCG
During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
干预措施: Corifollitropin alfa (Drug)
Corifollitropin alfa 150 μg + hCG
During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
干预措施: hCG (Drug)
结局指标
主要结局
Change From Baseline in Log-Transformed Testicular Volume at Week 52
时间窗: Baseline and Week 52
Participants underwent testicular ultrasound in the pretreatment phase at Weeks -16, -8, -1; and during the combined treatment phase at Baseline (predose, Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52. The testicular volume was measured as the sum of volumes of left and right testes. The mean change from Day 1 in log-transformed testicular volume was analyzed using a mixed model with a fixed effect for time point and a random effect for the participant. For each time point, the mean change from Day 1 to that time point and the associated 95% confidence interval (CI) was calculated. The geometric mean fold change in testicular volume and its 95% CI was obtained by exponentiation.
Percentage of Participants With Anti-Corifollitropin Alfa Antibodies
时间窗: Up to Week 57
Blood samples were collected for assessment of anti-corifollitropin alfa antibodies in the pretreatment phase at Week -16 and Week -1; during the combined treatment phase at Weeks 4, 16, 28, 50, 52; and at the post-treatment follow-up visit, which could occur from Week 53 up to Week 57.
次要结局
- Percentage of Participants With Induced Spermatogenesis Resulting in a Sperm Count ≥1x10^6/mL at or Before Week 52(Up to Week 52)